Wendy Bannister

1.4k total citations
29 papers, 938 citations indexed

About

Wendy Bannister is a scholar working on Oncology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Wendy Bannister has authored 29 papers receiving a total of 938 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Wendy Bannister's work include PARP inhibition in cancer therapy (13 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (7 papers). Wendy Bannister is often cited by papers focused on PARP inhibition in cancer therapy (13 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (7 papers). Wendy Bannister collaborates with scholars based in United Kingdom, Denmark and Netherlands. Wendy Bannister's co-authors include Jens Lundgren, Amanda Mocroft, Ole Kirk, Lisa M Wilson, Eamonn R. Maher, I. Karen Temple, William Reardon, L A Brueton, Alastair Sutcliffe and Catherine Peters and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Infectious Diseases.

In The Last Decade

Wendy Bannister

29 papers receiving 910 citations

Peers

Countries citing papers authored by Wendy Bannister

Since Specialization

Citations

This map shows the geographic impact of Wendy Bannister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Bannister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Bannister more than expected).

Fields of papers citing papers by Wendy Bannister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Bannister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Bannister. The network helps show where Wendy Bannister may publish in the future.

Co-authorship network of co-authors of Wendy Bannister

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Bannister. A scholar is included among the top collaborators of Wendy Bannister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Bannister. Wendy Bannister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial 2019 ·European Journal of Cancer ·Mark E. Robson, Kathryn J. Ruddy, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Wei Li, Nadine Tung, Anne Armstrong, Suzette Delaloge, Wendy Bannister, Carsten Goessl, Arnold Degboe, Robert Hettle, Pierfranco Conté	57
2	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment 2019 ·Clinical Pharmacokinetics ·Christian Rolfo, Judith de Vos‐Geelen, Nicolás Isambert, L. Rhoda Molife, Jan H.M. Schellens, Jacques De Grève, Luc Dirix, (unknown), Guy Jérusalem, Karin Leunen, Morten Mau‐Sørensen, Ruth Plummer, Maria Learoyd, Wendy Bannister, Anitra Fielding, Alain Ravaud	23
3	Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 2018 ·Cancer Research ·S. M. Domchek, Mark E. Robson, S-A. Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, (unknown), Anne Armstrong, Pierfranco Conté, Wendy Bannister, Carsten Goessl, Sarah Runswick, Sanjay Goel, Nadine Tung	3
4	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies 2016 ·Clinical Therapeutics ·Luc Dirix, Helen Swaisland, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jérusalem, Christian Rolfo, Dorte Nielsen, L. Rhoda Molife, Rebecca Kristeleit, Judith de Vos‐Geelen, Morten Mau‐Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Anitra Fielding, Karen So, Wendy Bannister, Ruth Plummer	47
5	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib 2016 ·Targeted Oncology ·Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, S.B. Kaye, Emma Dean, Mark R. Middleton, Michael Friedländer, Charlie Gourley, Ruth Plummer, Gordon Rustin, C. Sessa, Karin Leunen, Jonathan A. Ledermann, Helen Swaisland, Anitra Fielding, Wendy Bannister, Shibani Nicum, L Rhoda Molife	104
6	Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies 2016 ·Cancer Chemotherapy and Pharmacology ·Helen Swaisland, Ruth Plummer, Karen So, Sally Garnett, Wendy Bannister, (unknown), Corina Dota, Anitra Fielding	12
7	Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours 2015 ·Cancer Chemotherapy and Pharmacology ·Ruth Plummer, Helen Swaisland, Karin Leunen, Carla M.L. van Herpen, Guy Jérusalem, Jacques De Grève, Martijn P. Lolkema, Patricia M.M.B. Soetekouw, Morten Mau‐Sørensen, Dorte Nielsen, James Spicer, Anitra Fielding, Karen So, Wendy Bannister, L Rhoda Molife	47
8	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors 2015 ·Advances in Therapy ·Christian Rolfo, Helen Swaisland, Karin Leunen, Annemie Rutten, Patricia M.M.B. Soetekouw, Sarah Slater, Henk M.W. Verheul, Anitra Fielding, Karen So, Wendy Bannister, Emma Dean	40
9	Detection of transient regional myocardial ischemia using body surface Delta map in patients referred for myocardial perfusion imaging—A pilot study 2013 ·Journal of Electrocardiology ·(unknown), Florence Garty, (unknown), Wendy Bannister, Paul Roderick, Simon Corbett, John M. Morgan, Nick Curzen	2
10	The Coding Causes of Death in HIV (CoDe) Project 2011 ·Epidemiology ·Justyna Kowalska, Nina Friis‐Møller, Ole Kirk, Wendy Bannister, Amanda Mocroft, Caroline Sabin, Peter Reiss, M. John Gill, Charlotte Lewden, Andrew Phillips, Antonella d’Arminio Monforte, Matthew Law, Jonathan A C Sterne, Stéphane De Wit, Jens Lundgren	111
11	Tuberculosis among HIV-positive patients across Europe 2011 ·AIDS ·(unknown), Wendy Bannister, Daria Podlekareva, Nelly Chentsova, Aza Rakhmanova, Andrzéj Horban, (unknown), Amanda Mocroft, Jens Lundgren, Ole Kirk	20
12	Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam 2011 ·International Journal of STD & AIDS ·(unknown), Wendy Bannister, (unknown), Ole Kirk, Lars Peters	14
13	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Wendy Bannister, Alessandro Cozzi‐Lepri, Bonaventura Clotet, Amanda Mocroft, Jesper Kjær, Peter Reiss, Viktor von Wyl, Adriano Lazzarin, Christine Katlama, Andrew Phillips, Lidia Ruíz, Jens Lundgren	38
14	The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results 2008 ·Central European Journal of Public Health ·Daria Podlekareva, Wendy Bannister, Amanda Mocroft, (unknown), Igor Karpov, Jens Lundgren, Ole Kirk	12
15	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA 2008 ·AIDS ·Wendy Bannister, Lı́dia Ruiz, Alessandro Cozzi‐Lepri, Amanda Mocroft, Ole Kirk, Schlomo Staszewski, Clive Loveday, Anders Karlsson, Antonella d’Arminio Monforte, Bonaventura Clotet, Jens Lundgren	41
16	Incidence of abacavir hypersensitivity reactions in EuroSIDA 2008 ·Antiviral Therapy ·Wendy Bannister, Nina Friis‐Møller, Amanda Mocroft, Jean-Paul Viard, Jan van Lunzen, Ole Kirk, Panagiotis Gargalianos, Dénes Bánhegyi, Antonio Chiesi, Jens Lundgren, (unknown)	9
17	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Wendy Bannister, Ole Kirk, José M. Gatell, Brygida Knysz, Jean‐Paul Viard, Helene Mens, Antonella d’Arminio Monforte, Andrew Phillips, Amanda Mocroft, Jens Lundgren	29
18	Assisted reproductive therapies and imprinting disorders—a preliminary British survey 2005 ·Human Reproduction ·Alastair Sutcliffe, Catherine Peters, Sarah Bowdin, I. Karen Temple, William Reardon, Lisa M Wilson, Jill Clayton‐Smith, L A Brueton, Wendy Bannister, Eamonn R. Maher	186
19	Comparison of serum FSH and Inhibin B levels between adult male dizygotic and monozygotic twins 2005 ·Human Reproduction ·Alastair Sutcliffe, Helen Spoudeas, Devaki Nair, Pierre Bouloux, R.T.D. Oliver, Philip N. Sambrook, Wendy Bannister, Cornelis B. Lambalk, Tim D. Spector	2
20	Independent effects of the −219 G>T and ε2/ε3/ε4 polymorphisms in the apolipoprotein E gene on coronary artery disease: The Southampton Atherosclerosis Study 2003 ·European Journal of Human Genetics ·Shu Ye, (unknown), Wendy Bannister, Lorna Day, William Tapper, Andrew Collins, Ian N.M. Day, Iain A. Simpson	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact